The effect of curcumin on serum copper, zinc, and zinc/copper ratio in patients with β-thalassemia intermedia: a randomized double-blind clinical trial

Thalassemia intermedia is a subgroup of β-thalassemia which originates from mutations in the beta-globin gene. Zinc and copper play important roles in the metabolism. Due to its significant therapeutic effects, curcumin has led many studies to focus on curcumin. In a double-blind clinical trial stud...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hematology 2021-03, Vol.100 (3), p.627-633
Main Authors: Saeidnia, Mohammadreza, Nowrouzi-Sohrabi, Peyman, Erfani, Mehran, Fazeli, Pooria, Tamaddon, Gholamhossein, Karimi, Mehran
Format: Article
Language:English
Subjects:
Administration, Oral
Adult
beta-Thalassemia - blood
beta-Thalassemia - drug therapy
Blood Chemical Analysis
Capsules
Clinical trials
Copper
Copper - analysis
Copper - blood
Curcumin - administration & dosage
Curcumin - pharmacology
Double-Blind Method
Double-blind studies
Ferritins - analysis
Ferritins - blood
Hematology
Humans
Iran
Male
Medicine
Medicine & Public Health
Oncology
Original Article
Young Adult
Zinc - analysis
Zinc - blood
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Thalassemia intermedia is a subgroup of β-thalassemia which originates from mutations in the beta-globin gene. Zinc and copper play important roles in the metabolism. Due to its significant therapeutic effects, curcumin has led many studies to focus on curcumin. In a double-blind clinical trial study, 30 patients with beta-thalassemia intermedia with an age range of 20 to 35 years were randomly selected 1:1 to receive either curcumin or placebo for 3 months. Before and after the intervention period, 5 ml of blood was taken to determine the serum levels of zinc and copper. The laboratory tests were checked at baseline and at the end of the treatment. While the serum levels of zinc and zinc/copper significantly increased, the serum levels of copper decreased after 3 months of curcumin intake. In addition, on the basis of baseline characteristics, a negative correlation was found between zinc and body mass index and positive correlations were identified between copper with triglyceride and high-density lipoprotein. Also, the level of ferritin protein in the curcumin group compared to the placebo group showed a significant decrease after 3 months of curcumin use. Therefore, it could be concluded that curcumin might exert a net protective effect on copper toxicity in thalassemia intermedia patients. The investigation also implicated that curcumin represents an approach to regulating zinc homeostasis and may be useful as a complementary treatment of patients with thalassemia intermedia, especially in patients with zinc deficiency or low serum zinc/copper ratio. Clinical Trial Registration Number: IRCT20190902044668N1
ISSN:0939-5555
1432-0584
DOI:10.1007/s00277-021-04397-z